Vandetanib for the second and subsequent line treatment of non-small cell lung cancer after previous platinum containing chemotherapy
|
Status
|
Suspended
|
|
Decision
|
Selected
|
| Process |
STA pre-2018
|
| Referral date |
01 November 2008 |
|
Topic area
|
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: |
TBC |
| 1st appraisal committee meeting: |
TBC |
Project Team
| Communications manager: |
Alice Law |
| Executive Lead: |
Andrew Stevens |
| Project manager: |
Laura Malone |
| Technical Lead: |
Sally Gallaugher |
|
Date
|
Update
|
|
25 November 2009
|
The manufacturer of vandetanib has advised us that regulatory approval for this technology in the second and subsequent line setting is not being sought at this time. The Institute has therefore decided to remove this appraisal from its current work programme. As this topic has been referred to the Institute, we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email: cathryn.hall@nice.org.uk) |
For further information on our processes and methods, please see our CHTE processes and methods manual